Related Experiment Videos
Intracranial hemorrhage after thrombolytic therapy. A perspective
M L Simoons1, P de Jaegere, R van Domburg
1Thoraxcenter, Erasmus University, The Netherlands.
Zeitschrift Fur Kardiologie
|January 1, 1993
Summary
Thrombolytic therapy offers significant survival benefits that outweigh bleeding risks for most patients treated within 12 hours. However, it is not recommended for elderly patients with small infarcts and multiple hemorrhage risk factors.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Emergency Medicine
Background:
- Intracranial hemorrhage is a major concern with thrombolytic therapy.
- Thrombolysis offers substantial benefits in stroke treatment.
- Risk-benefit assessment is crucial for patient selection.
Purpose of the Study:
- To evaluate the net benefit of thrombolytic therapy.
- To identify patient subgroups who benefit most from thrombolysis.
- To define criteria for withholding thrombolytic therapy.
Main Methods:
- Calculating expected patient benefit by subtracting hemorrhage risk from survival gain.
- Analyzing patient factors influencing thrombolysis outcomes.
- Assessing treatment efficacy within the first 12 hours of symptom onset.
Main Results:
- Thrombolysis is beneficial for most patients treated within 12 hours, even with some risk factors.
- Elderly patients with small infarcts and multiple risk factors for intracranial hemorrhage may not benefit.
- Individualized risk-benefit analysis is key to optimizing thrombolytic therapy.
Conclusions:
- Thrombolytic therapy provides significant survival advantages that generally outweigh intracranial hemorrhage risks.
- Treatment timing and patient-specific factors, including age and comorbidities, are critical for decision-making.
- Careful patient selection ensures optimal outcomes and minimizes potential harm from thrombolysis.